Christopher J. Wilson

Christopher J. Wilson

Auto-generated profile, based on publicly available information

Christopher J. Wilson

Geisinger Medical Center

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2009 in Cell
Verified
Journal Article
Closed access
PNPaul Nicklin
Paul Nicklin
PBPhilip Bergman
Philip Bergman
BZBailin Zhang
Bailin Zhang
ETEllen Triantafellow
Ellen Triantafellow
HWHenry Wang
Henry Wang
LMLeon O. Murphy
Leon O. Murphy

22 December 2000 in Science
Verified
Journal Article
Closed access
PDF file
BRBing Ren
Bing Ren
FRFrançoIs Robert
FrançoIs Robert
JWJohn J. Wyrick
John J. Wyrick
OAOscar M Aparicio
Oscar M Aparicio
EJEzra G. Jennings
Ezra G. Jennings
RYRichard A. Young
Richard A. Young
Understanding how DNA binding proteins control global gene expression and chromosomal maintenance requires knowledge of the chromosomal locations at which these proteins function in vivo. We developed a microarray method that reveals the genome-wide location of DNA-bound proteins and used this method to monitor binding of gene-specific transcription activators in yeast. A combination of location and expression profiles was used to identify genes whose expression is directly controlled by Gal4 and Ste12 as cells respond to changes in carbon source and mating pheromone, respectively. The results identify pathways that are coordinately regulated by each of the two activators and reveal previously unknown functions for Gal4 and Ste12. Genome-wide location analysis will facilitate investigation of gene regulatory networks, gene function, and genome maintenance.

24 November 2010 in Nature
Verified
Journal Article
Open access
PDF file
CJCory M. Johannessen
Cory M. Johannessen
JBJesse S. Boehm
Jesse S. Boehm
SKSo Young Kim
So Young Kim
STSapana R. Thomas
Sapana R. Thomas
LWLeslie Wardwell
Leslie Wardwell
LGLevi A. Garraway
Levi A. Garraway
Clinical trials in melanoma patients carrying B-RAF gene mutations have shown promising results with the B-RAF kinase inhibitor PLX4032, but many patients go on to become resistant. Two papers now uncover possible mechanisms for this resistance. Nazarian et al. report that melanomas can acquire resistance due to mutations of N-RAS or increased expression of PDGFRβ, and Johannessen et al. report resistance due to upregulation of MAP3K8/COT. Each of these mechanisms seems to apply to some patients in the recent PLX4032 trial, yet surprisingly, no secondary B-RAF mutations were observed. Recent data from early clinical trials in melanoma patients carrying mutations in the B-RAF gene have shown promising results with the B-RAF kinase inhibitor PLX4032; however, many patients eventually develop resistance to this treatment. Two papers now uncover possible mechanisms of resistance to PLX4032. One paper shows that upregulation of MAP3K8 (which encodes COT) can confer resistance of melanoma cells to B-RAF inhibitors, whereas another paper found that melanomas can acquire resistance due to mutations of N-RAS or increased expression of PDGFRβ. Each of these resistance mechanisms seems to apply to at least some patients on recent PLX4032 trial, whereas, surprisingly, so far no secondary B-RAF mutations have been observed. Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50–70% of malignant melanomas1. Pre-clinical studies have demonstrated that the B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma2,3,4,5,6—an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials7,8,9. However, clinical responses to targeted anticancer therapeutics are frequently confounded by de novo or acquired resistance10,11,12. Identification of resistance mechanisms in a manner that elucidates alternative ‘druggable’ targets may inform effective long-term treatment strategies13. Here we expressed ∼600 kinase and kinase-related open reading frames (ORFs) in parallel to interrogate resistance to a selective RAF kinase inhibitor. We identified MAP3K8 (the gene encoding COT/Tpl2) as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines. COT activates ERK primarily through MEK-dependent mechanisms that do not require RAF signalling. Moreover, COT expression is associated with de novo resistance in B-RAF(V600E) cultured cell lines and acquired resistance in melanoma cells and tissue obtained from relapsing patients following treatment with MEK or RAF inhibitors. We further identify combinatorial MAPK pathway inhibition or targeting of COT kinase activity as possible therapeutic strategies for reducing MAPK pathway activation in this setting. Together, these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies.

19 October 2014 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
WDWilliam E. Dowdle
William E. Dowdle
BNBeat Nyfeler
Beat Nyfeler
JNJane Nagel
Jane Nagel
RERobert A. Elling
Robert A. Elling
SLShanming Liu
Shanming Liu
LMLeon O. Murphy
Leon O. Murphy

21 January 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MMMorgan L. Maeder
Morgan L. Maeder
MSMichael Stefanidakis
Michael Stefanidakis
CWChristopher J. Wilson
Christopher J. Wilson
RBReshica Baral
Reshica Baral
LBLuis Alberto Barrera
Luis Alberto Barrera
HJHaiyan Jiang
Haiyan Jiang

1 February 2012 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
SMSauveur-Michel Maira
Sauveur-Michel Maira
SPSabina Pecchi
Sabina Pecchi
AHAlan Huang
Alan Huang
MBMatthew Burger
Matthew Burger
MKMark Knapp
Mark Knapp
CVCharles F. Voliva
Charles F. Voliva
Following the discovery of NVP-BEZ235, our first dual pan-PI3K/mTOR clinical compound, we sought to identify additional phosphoinositide 3-kinase (PI3K) inhibitors from different chemical classes with a different selectivity profile. The key to achieve these objectives was to couple a structure-based design approach with intensive pharmacologic evaluation of selected compounds during the medicinal chemistry optimization process. Here, we report on the biologic characterization of the 2-morpholino pyrimidine derivative pan-PI3K inhibitor NVP-BKM120. This compound inhibits all four class I PI3K isoforms in biochemical assays with at least 50-fold selectivity against other protein kinases. The compound is also active against the most common somatic PI3Kα mutations but does not significantly inhibit the related class III (Vps34) and class IV (mTOR, DNA-PK) PI3K kinases. Consistent with its mechanism of action, NVP-BKM120 decreases the cellular levels of p-Akt in mechanistic models and relevant tumor cell lines, as well as downstream effectors in a concentration-dependent and pathway-specific manner. Tested in a panel of 353 cell lines, NVP-BKM120 exhibited preferential inhibition of tumor cells bearing PIK3CA mutations, in contrast to either KRAS or PTEN mutant models. NVP-BKM120 shows dose-dependent in vivo pharmacodynamic activity as measured by significant inhibition of p-Akt and tumor growth inhibition in mechanistic xenograft models. NVP-BKM120 behaves synergistically when combined with either targeted agents such as MEK or HER2 inhibitors or with cytotoxic agents such as docetaxel or temozolomide. The pharmacological, biologic, and preclinical safety profile of NVP-BKM120 supports its clinical development and the compound is undergoing phase II clinical trials in patients with cancer. Mol Cancer Ther; 11(2); 317–28. ©2011 AACR.